drugset / Trial / NCT02284503

Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With Non ST-segment Elevated Acute Coronary Syndrome(NSTE-ACS)

NCT02284503 ↗

Phase 4 Unknown 1350 enrolled Shanghai Zhongshan Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a 30-day, randomized, open-label, 3-arm, parallel-group, multicenter study exploring efficacy of intensive rosuvastatin treatment peri-PCI in Chinese patients with NSTE-ACS.

Timeline

Start
2014-11
Primary completion
2014-12
Completion
2016-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 10 mg —
Subject Rosuvastatin Small molecule 20 mg —
Subject Rosuvastatin Small molecule 40 mg —